Dietary supplement based on dihydromyricetin in metabolic dysfunction-associated steatotic liver disease: a double-blind, placebo-controlled, randomized clinical trial.

Ann Gastroenterol · 2026 · PMC12850692 · PMID 41612982

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Both enzymes tended to improve slightly in the DHM group compared with placebo, but these changes did not reach statistical significance ( Table 4 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.